Product Description:

Nindanix is indicated for the treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) adenocarcinoma type in combination with docetaxel for the treatment of adult patients after the failure of first-line chemotherapy.

Product Features:

Product Name Nindanix
Generic Name Nintedanib
Formulation Capsule
Available Pack Size 80 & 50 Capsule
Available Strength 100 mg, 150 mg
Registrations Available